ANZCTR search results

Left bundle branch pacing (LBBP) is rapidly emerging pacing therapy. Traditionally, lumenless fixed helix lead is used for LBBP which is delivered through a fixed curve or preshaped flexible curve delivery catheter. Left bundle area can also be captured with implantation of traditional stylet-driven leads delivered with the use of various delivery sheaths from different manufacturers. Currently, both techniques are in use; however, data regarding comparison of outcomes of these two different lead systems is limited. This trial aims at comparing the outcomes of these two different techniques of LBBP which are currently in use.

Nausea and vomiting are common reasons for people to call an ambulance. In Queensland, paramedics can provide a medication called ondansetron to reduce the severity of nausea and vomiting. Alternative medicines, such as metoclopramide and droperidol, are also used in the emergency department or by ambulance services in other states. This study aims to determine the effectiveness of medicines for nausea and vomiting in the prehospital environment. We will randomly assign patients who have nausea and/or vomiting to receive either ondansetron, metoclopramide, droperidol or a placebo as a prehospital treatment. We hypothesise that the proportion of patients experiencing symptom relief will be higher in the 3 medication compared to placebo groups

The aim of this study is to assess the feasibility and accuracy of a novel point of care test to predict foot ulcer healing in people with diabetes. Specifically to define whether a point of care test (InflammaDry) measuring Matrix Metalloproteinase-9 (MMP-9) in wound fluid obtained from diabetes related foot ulcers is feasible when used in a interdisciplinary High Risk Foot Service (iHRFS) and can reflect laboratory MMP-9 measures accurately, so to then predict ulcer healing outcome. Secondary aims are to determine if topical application of a dried human tissue allograft derived from placental membrane (Revita) may improve the healing trajectory of foot ulcers in people with diabetes whose ulcers despite receiving optimized care in a iHRFS are not demonstrating signs of healing. If we can show that we can analyse MMP-9 at the chair-side during consultation at the time of treating the foot ulcer and determine if this test can predict healing outcomes, then in the future we could make a timely decision at the same patient consultation in the interdisciplinary High Risk Foot Service to apply intensified therapy such as Revita® treatment. Together these studies will determine whether these MMP-9 POCT is feasible, if other biomarkers can in a complementary manner, predict the healing outcomes, and whether the Revita® treatment is well tolerated and could improve wound healing in people with delayed wound healing in diabetes.

The global healthcare workforce has been described as being in a state of burnout since the global pandemic. Burnout is a three-dimensional condition often resulting from chronic work-related stress, encompassing exhaustion or energy depletion, depersonalisation and a sense of ineffectual accomplishment. The aim of this study is to assess whether a combination of nutritional and herbal intervention is effective in individuals experiencing fatigue associated with burnout but who are otherwise healthy. This 10-week randomised, controlled pilot trial comprises four assessment points: baseline, (Study Clinic 1 ) 1 month later (Study Clinic 2), with the final clinic one month later (Study Clinic 3 ) and a follow up (2 weeks post study clinic 3). The primary outcomes are feasibility and safety measures. Secondary outcomes are burnout severity, measured by the Sydney Burnout Measure (three factors: physical fatigue, behaviours dysfunction, emotional) measured monthly, the Warwick-Edinburgh Mental Well-being Scale (measured monthly), the Fatigue Severity Scale (measured monthly), and a Patient-reported Outcome Measure, such as the Patient Specific Scale (measured monthly).

This project aims to create pilot data to determine associations between MRI images as a clinical measure of MS progress and high quality dietary intake and lifestyle data. It is hypothesised that by using objective measures of disease outcomes using high resolution images obtained on a consistent quality scanner will allow for clearer associations between clinical progress and lifestyle management to be explored.

Malnutrition, sarcopenia, and cachexia are common concerns for patients with pancreatic cancer, causing increased risk of comorbidities and may affect their ability to respond to cancer treatments. This study aims to assess the feasibility and effectiveness of an out-patient dietetics program on nutritional status and quality of life in individuals with pancreatic cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with pancreatic cancer and you are due to begin your cancer therapy within the next month. Study details You will be assessed by a dietitian within the first month of your treatment. Basic health and nutrition information will be collected including your age, weight, cancer stage and treatment, symptoms impacting your nutrition (such as nausea, vomiting, or treatment side effects), and diet history. Individual nutrition recommendations will be provided to optimise your nutritional intake, which might involve consuming oral nutrition supplements. If you have not started therapy, education will be provided regarding your upcoming treatment and how this might impact your nutrition afterwards. The number of times you will be seen by a dietitian will depend on your nutrition status and how much support you require. You will be requested to complete questionnaires to help us understand your nutritional status, quality of life, and satisfaction with the dietetics program. It is hoped this research will determine that dietary counselling for patients with pancreatic cancer is feasible and acceptable to these patients. This pilot study will assess whether there is potential benefit in delivering this service to a greater number of patients with pancreatic cancer in a larger randomised trial.

ECMO-PROMPT is a trial that focuses on improving the long-term disability, functional status and health outcomes for survivors of ECMO therapy. Providing the results of patient reported outcome measures (PROMs) to patients and their primary care clinicians at hospital discharge and beyond, is an intervention used in other patient groups to support the transition from hospital to home. In this study, ECMO survivors will have PROM monitoring. The intervention group will receive feedback and recommendations.

This research study aims to look at whether physiotherapists working in the Neonatal Intensive Care Unit (NICU) can identify changes in babies’ lungs to the same level as a neonatologist using Lung Ultrasound (LUS) scans. Physiotherapists working in the NICU may provide chest physiotherapy (CPT) to preterm babies to help treat certain respiratory pathologies. Not all preterm babies require CPT and currently physiotherapists use multiple assessment tools to identify appropriate babies in lieu of a single existing Gold Standard measurement tool. Current assessment tools have inherent challenges and are not considered clinimetrically robust. LUS has been suggested as a new physiotherapy assessment tool because of its high level of valid, reliable and feasible lung imaging, that can be performed in real-time by the bedside, without exposing babies to radiation. This project will investigate whether neonatal physiotherapists can reliably interpret LUS scans compared to an experienced neonatologist. Results may allow physiotherapists to use LUS as an assessment tool in the future to help more safely and correctly identify babies who may benefit from chest physiotherapy.

The primary purpose of this study is to evaluate the clinical effectiveness of LUS compared to routine chest physiotherapy outcome measures in determining the need for and effect of physiotherapy on neonates. This will be done by comparing whether LUS is better at guiding CPT treatment than looking at the lungs with CXR and listening to the lungs using a stethoscope. Results may help us improve how CPT is delivered to babies in the future.

The GIFT Trial is a randomised, controlled, blinded, parallel group trial to compare the effect of supplementary pasteurised donor human milk versus infant formula on length of neonatal hospital stay, morbidity, breastfeeding, growth, development and health care costs in clinically well pre-term infants born between 32+0 and 36+6, with a birth weight >=1500g and with insufficient maternal breast milk available. The GIFT Trial hypothesises that the use of donor milk instead of infant formula, as a supplement to maternal breast milk, in moderate-late preterm infants will reduce the time spent in hospital after birth.